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Drug-induced long QT syndrome (LQTS) is a prevalent disorder of
uncertain etiology that predisposes to sudden death. KCNE2 en-
codes MinK-related peptide 1 (MiRP1), a subunit of the cardiac
potassium channel IKr that has been associated previously with
inherited LQTS. Here, we examine KCNE2 in 98 patients with
drug-induced LQTS, identifying three individuals with sporadic
mutations and a patient with sulfamethoxazole-associated LQTS
who carried a single-nucleotide polymorphism (SNP) found in
’1.6% of the general population. While mutant channels showed
diminished potassium flux at baseline and wild-type drug sensi-
tivity, channels with the SNP were normal at baseline but inhibited
by sulfamethoxazole at therapeutic levels that did not affect
wild-type channels. We conclude that allelic variants of MiRP1
contribute to a significant fraction of cases of drug-induced LQTS
through multiple mechanisms and that common sequence varia-
tions that increase the risk of life-threatening drug reactions can be
clinically silent before drug exposure.
MiRP1 u LQTS u SNP u Bactrim u sulfamethoxazole
Inherited long QT syndrome (LQTS) is an uncommon cardiacarrhythmia that predisposes to torsades de pointes (TdP),
ventricular fibrillation, and sudden death (1–4). The molecular
basis for LQTS is known: delayed repolarization of the myocar-
dium prolongs the cardiac action potential increasing the QT
interval measured on the surface electrocardiogram. Mutations
in five ion channel genes cause the majority of cases of inherited
LQTS. LQTS mutations in SCN5A increase activity of the
sodium channel that depolarizes the myocardium to initiate the
cardiac action potential (5); LQTS mutations in KCNE1 or
KvLQT1 (encoding subunits of IKs channels) and KCNE2 or
HERG (encoding subunits of IKr channels) diminish potassium
fluxes that repolarize the heart to end each beat (6–9).
Acquired LQTS is a common disorder caused by drugs and
metabolic abnormalities. The risk for acquired LQTS increases
when factors that decrease potassium flux act concurrently to
impair the ability of the myocardium to repolarize. Well-
recognized conditions that diminish ‘‘repolarization reserve’’
include female gender, hypokalemia, and drugs that inhibit
cardiac potassium channels (10). Several lines of evidence
suggest that patients with drug-induced LQTS have an under-
lying predisposition to dysrrhythmia. The QT interval measured
before drug exposure tends to be longer in patients who later
develop drug-induced LQTS than in individuals who receive the
same agent safely (11, 12). Moreover, sporadic mutations have
been identified in patients with drug-induced TdP (9, 13, 14).
Thus, we demonstrated previously that patients with ‘‘acquired’’
LQTS can have a genetic predisposition to arrhythmia because
of mutation in the MinK-related peptide 1 (MiRP1) subunit of
their IKr potassium channels (9). In that study, a woman with
clarithromycin-induced TdP was found to carry a sporadic
missense mutation in KCNE2; channels formed with the altered
subunit (Q9E-MiRP1) were abnormal at baseline because they
activated less readily (and so passed less potassium); moreover,
Q9E-MiRP1 channels were 3-fold more sensitive to drug inhi-
bition than wild type. In that case, a rare mutation increased the
risk of drug-induced TdP by both decreasing repolarization
reserve and increasing sensitivity to an agent that is usually well
tolerated.
Here we examine KCNE2 in 98 patients with drug-induced
arrhythmia and identify four missense variants, three mutations
that diminish potassium flux at baseline (M54T-, I57T- and
A116V-MiRP1) and a single-nucleotide polymorphism (SNP)
producing T8A-MiRP1 that is present in ’1.6% of healthy
individuals (9). Our patient with the SNP had a normal elec-
trocardiogram at rest but developed a very long QT interval on
Bactrim [trimethoprimysulfamethoxazole (TMPySMX)] ther-
apy. The apparent etiology: channels formed with T8A-MiRP1
are inhibited by SMX at levels present in the sera of patients on
TMPySMX.
Materials and Methods
Study Subjects. The femaleymale ratio in this study population
was 2:1, and 95 patients were Caucasian. Informed consent was
obtained from each subject approved by the Vanderbilt Univer-
sity Institutional Review Board.
Mutation Analysis. The GenBank accession number for human
KCNE2 encoding MiRP1 is AF071002. Genomic DNA was
isolated from peripheral blood leukocytes by standard methods
and two overlapping regions of the KCNE2 coding sequence
screened for the presence of nucleotide sequence polymorphism
by single-strand conformational polymorphism (SSCP) analysis
(15). Oligonucleotide primer pairs used to amplify the KCNE2
coding sequence were: section I (nucleotides 32–259 of accession
no. AF071002), forward primer: 59-TGT TCG CCT ATT TTA
TTA TTT-39; reverse primer: 59-AAA GAG AAC ATT CCA
ATC AT-39; section II (corresponding to nucleotides 212-471),
forward primer: 59-TAC TAT GTC ATC CTG TAC CTC-39;
reverse primer: 59-GTT AGC TTG GTG CCT TTC T-39.
Amplification reactions were carried out by using 200 ng
genomic DNA, 0.5 mM primers, 0.2 mM deoxynucleotide
triphosphates, and Taq polymerase. SSCP analysis was per-
formed on 0.53 mutation detection electrophoresis (MDE) gels
subjected to overnight electrophoresis at 4 W and stained with
silver nitrate. Abnormal conformers were excised from dried
gels, eluted into sterile water at room temperature, reamplified
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by using the original primers, and sequenced by using dye
terminator chemistry. The presence of the KCNE2-A116V mu-
tation was confirmed independently on PCR amplified genomic
DNA by using an allele-specific hybridization assay with a 32P
end-labeled primer: 59-AAC ATT GGT GTG GCT GGG TT-39.
Heterologous Expression. Mutations identified in patients were
produced in wild-type human KCNE2 in pGA1 (9) by plaque-
forming unit-based mutagenesis (QuickChange Kit; Stratagene,
La Jolla, CA) followed by insertion of mutant gene fragments
into translationally silent restriction sites in the wild-type con-
struct and confirmed by automated DNA sequencing. Transient
transfection of Chinese hamster ovary (CHO) cells was by
DEA-Dextran, Chloroquine, and DMSO shock with KCNE2 and
HERG (Human ether a-go-go related gene) in pCl-neo-based
vectors (Invitrogen) as before (9).
Electrophysiology. Data were recorded by using an Axopatch 200
B amplifier (Axon Instruments, Foster City, CA), a Quadra 800
Macintosh computer and PULSE software (Heka Electronics,
LombrechtyPfalz, Germany). Sampled at 1 kHz, data are pre-
sented as mean 6 SEM. All experiments were performed at
room temperature. Holding voltage was 280 mV. Standard
voltage protocol: 1-s prepulse from 260 to 20 mV in 10-mV step
followed by 2-s step to 240 mV with a 1-s interpulse interval.
Simulated cardiac action potential protocol: voltage ramp from
40 to 280 mV with a rate of change of 271 mV per second. Data
are presented after ohmic leak subtraction (standard protocol)
or subtraction of residual current after full drug block (simulated
action potential). If leak was greater than 25% of total current,
cells were discarded. The bath solution was (in mM): 100 NaCly4
KCly1 CaCl2y0.7 MgCl2y10 Hepes, pH 7.5 with NaOH. The
pipette solution was (in mM): 100 KCly10 Hepesy1 MgCl2y2
EGTA, pH 7.5 with KOH. Stock solutions of oxatomide (Jensen,
Spring House, PA), quinidine (Sigma), and procainamide (Sig-
ma) were prepared by dissolution in bath solution at concen-
trations of 0.01, 1, and 10 mM, respectively. Oxatomide solution
was prepared fresh daily. Sulfamethoxazole and trimethoprim
(Sigma) are poorly soluble in water and were dissolved in ethanol
at 100 mM or methanol at 20 mM, respectively. Solutions were
then prepared daily by diluting stocks in bath solution. Sulfa-
methoxazole and trimethoprim were mixed 1:5 by weight as in
TMPySMX; control solutions for these studies were supple-
mented with equal levels of ethanol andyor methanol.
Results and Discussion
To examine the basis for drug-induced LQTS, genomic DNA
samples were obtained from 98 patients who experienced ex-
cessive prolongation of the QT interval (.600 msec) or who
developed TdP during drug treatment (see Materials and Meth-
ods). As KCNE2 consists of a single coding exon (encoding a
peptide of just 123 amino acids), it was amplified readily in two
overlapping segments from genomic DNA, allowing the coding
region to be screened for sequence polymorphism (Materials and
Methods). Three sporadic mutations and one common polymor-
phism were found in four patients in our population. Mutations
were identified that encoded M54T-, I57T-, and A116V-MiRP1;
the first two were previously identified in patients with sporadic
LQTS (9). One patient carried a polymorphism producing
T8A-MiRP1, a KCNE2 variant seen previously in 16 of 1,010
control individuals (9). The positions of these residues relative
to the cell membrane are indicated on a schematic rendition of
the predicted topology of MiRP1 (16) (Fig. 1A).
The KCNE2 mutation that substituted threonine for methio-
nine at amino acid 54 (M54T) was found in a patient who
presented with procainamide-induced LQTS. This mutation was
Fig. 1. KCNE2 missense mutations diminish IKr current density. (A) KCNE2 polymorphisms identified in patients with acquired LQTS. Schematic of the predicted
primary sequence and membrane topology of human MiRP1: a single transmembrane segment is based on the predicted sequence of MiRP1and its homology
to MinK; an externally-oriented amino-terminal domain is based on antibody localization (9). Residues that were altered in patients in this study are indicated.
(B) Current density assessed by normalizing steady-state tail currents at 240 mV to the cell capacitance for CHO cells expressing the indicated MiRP1 variants and
HERG and studied by the standard protocol (Materials and Methods). Each bar represents the mean 6 SEM for a group of 34–40 cells; the mean decrease in current
density compared with wild-type MiRP1 was 15, 39, 34, and 47% for T8A-MiRP1, M54T-MiRP1, I57T-, and A116V-MiRP1, respectively, with P , 1024 for each
variant compared with wild type (unpaired t test).
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seen once before among 230 patients with sporadic LQTS but
not in 1,010 controls (9); the antiarrhythmic medication
procainamide has been associated with acquired LQTS
previously (1).
The missense mutation that substituted a threonine for iso-
leucine at residue 57 (I57T) was found in a patient with a
prolonged QT interval induced by the histamine H1 receptor
antagonist oxatomide. This mutation was seen once before
among 230 patients with sporadic LQTS (9); oxatomide has not
been associated previously with dysrrhythmia.
A novel missense mutation substituting valine for alanine at
position 116 (A116V) was found in a 55-year-old white female
with a history of cardiac arrest associated with cocaine and
alcohol abuse. Subsequent treatment with quinidine and mexi-
letine was tolerated for 6 years. After mexiletine was discontin-
ued, she had syncope with TdP while on quinidine alone.
Evaluation at that time also revealed new-onset heart failure.
Sequence analysis revealed a C-to-T transition that was not
detected in 1,010 control individuals evaluated previously (9) or
in 200 control genes assessed in this study by an allele-specific
hybridization assay. The antiarrhythmic quinidine has been
associated with acquired LQTS (1).
A fourth missense variant was identified in a 45-year-old white
male with a history of Marfan syndrome who had a normal QT
interval at baseline but developed marked QT prolongation after
three oral doses of TMPySMX for treatment of a minor
infection. Screening revealed a polymorphism that substituted
alanine for threonine at MiRP1 position 8 (T8A). This KCNE2
polymorphism was previously seen in 16 of 1,010 control indi-
viduals, 1 of 230 patients with sporadic LQTS, and 1 patient with
quinidine-induced dysrrhythmia among 20 individuals with
drug-induced arrhythmia (9).
To investigate the effects of changes in KCNE2 on channel
function, the properties of wild-type and mutant MiRP1yHERG
channels were studied by transient expression in CHO cells in
whole-cell patch-clamp configuration, as described before (Ma-
terials and Methods) (9). The three sporadic mutations (M54T-,
I57T- and A116V-MiRP1) produced reductions of 34–47% in
current density at 240 mV (that is, whole-cell current divided by
membrane capacitance to normalize for cell size), whereas only
a 15% decrease was observed with T8A-MiRP1 (Fig. 1B). This
was compatible with our prior study showing that channels with
M54T-MiRP1 activated less readily and deactivated more rap-
idly than channels formed with either wild type or T8A-MiRP1
(9). Consistent with these observations, patients carrying M54T-
MiRP1 showed slightly prolonged QT intervals in the drug-free
state, whereas the patient with T8A-MiRP1, like 17y18 individ-
uals with this genotype studied previously (9), had a normal QT
interval at baseline.
The three sporadic mutations identified in our patients with
drug-induced LQTS did not alter sensitivity to drug inhibition.
Fig. 2A shows currents carried by channels formed with wild-type
MiRP1 or A116V-MiRP1 in the absence and presence of
quinidine; the two channels showed the same sensitivity to
equilibrium blockade (Fig. 2B). Similarly, channels with wild-
type MiRP1 or M54T-MiRP1 showed the same sensitivity to
procainamide (with equilibrium inhibition constants, Ki, of
190 6 30 and 185 6 35 mgyml, n 5 6, respectively), and those
with wild-type MiRP1 and I57T-MiRP1 had the same sensitivity
to oxatomide (Ki 5 0.18 6 0.05 and 0.18 6 0.04 mgyml, n 5 5,
respectively). Of note, levels of quinidine and oxatomide that
achieved half-maximal inhibition of channels in experimental
cells were close to their therapeutic concentrations in the plasma
of patients (17, 18). In contrast, procainamide and its principle
metabolite N-acetylprocainamide achieved half-maximal block-
ade at levels over 50-fold higher than those found in plasma (19);
the metabolite was even less potent than the parent compound
(Ki 5 400 6 60 and 390 6 70 mgyml for wild-type MiRP1 and
M54T-MiRP1, n 5 5, respectively). This suggests the proar-
rhythmic effects of procainimide may not be mediated by IKr
channels.
Wild-type and T8A-MiRP1 channels were studied with
TMPySMX, as this agent was associated with a prolonged QT
interval in our patient (Fig. 3). Although both channel types were
blocked, those with T8A-MiRP1 were ’2-fold more sensitive to
TMPySMX (Fig. 3A). Each active compound, TMP and SMX, was
Fig. 2. IKr channels formed with A116V-MiRP1 show wild-type blockade by quinidine. CHO cells expressing wild-type MiRP1 or A116V-MiRP1 and HERG were
studied by whole-cell clamp. (A) Whole-cell currents recorded from channels formed with wild-type MiRP1 (WT) and A116V-MiRP1 (A116V) in the absence (left
column) or presence of 0.5 mgyml of quinidine (1quinid). Scale bars represent 50 and 30 pA and 0.7 s for wild type and A116V-MiRP1, respectively. (Inset) Protocol:
holding 280-mV, 1-s pulses from 260 to 20 mV in 10-mV steps, 2 s at 240 mV, 1-s interpulse interval. (B) Current–dose relationship for channels formed with
wild-type MiRP1 (open circles) and A116V-MiRP1 (filled squares) in the presence of increasing amounts of quinidine. Data from peak currents at 240 mV after
a prepulse to 120 mV by using the standard protocol. Theoretical lines were constructed to the function: 1y(1 1 H) were H 5 ([drug]yKi)n. Ki and n represent
the equilibrium dissociation constant and the Hill coefficient, respectively. Fits give values for Ki and n of 0.41 6 0.04 mgyml and 1.1 6 0.1 for wild-type MiRP1
and 0.43 6 0.06 mgyml and 1.1 6 0.2 for A116V-MiRP1; 6 cells in each case.
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then investigated separately. Fig. 3B shows that TMP inhibited both
channels with similar affinity (Ki ’ 75 mgyml); a level of the agent
far in excess of its usual plasma level, ’5 mgyml (20, 21). In
contrast, SMX (633 mgyml) had almost no effect on wild-type
channels but inhibited more than half the flux through channels
formed with T8A-MiRP1 at 240 mV (Fig. 3C). Channels with
T8A-MiRP1 were at least 4-fold more sensitive to SMX than wild
type (Fig. 3D). It seems reasonable to ascribe the proarrhythmic
effects of Bactrim in our patient to its SMX component as serum
levels for this agent can exceed 300 mgyml (20, 21).
A notable difference in the effect of SMX on channels formed
with T8A-MiRP1 and wild-type MiRP1 was apparent when gating
kinetics were evaluated; the drug speeded deactivation (closure)
only of channels with the SNP (Table 1). Thus, SMX increased both
the fast and slow deactivation time constants for T8A-MiRP1
channels (enhancing tfast and tslow ’4- and 2-fold, respectively) but
had no significant effect on wild-type channels. As shown before
(9), channels with the SNP showed a small shift in their half-
maximal activation voltage (V1/2) but no change in slope factor (Vs)
compared with wild type (Table 1); SMX had no significant effect
on the V1/2 or Vs of either channel (Table 1).
To approximate the in vivo case with experimental cells, we used
a voltage protocol that mimics a cardiac action potential (22) in the
presence of physiological levels of drugs associated with LQTS in
our patients. Flux of potassium across the membrane in each cycle
was estimated from the area under the current curve. Fig. 4A shows
raw traces of currents passed by wild-type MiRP1 or A116V-MiRP1
channels in the absence and presence of 0.5 mgyml quinidine. At
baseline, the mutant channels pass 46 6 6% less potassium than
wild type (n 5 5). The two channel types were similarly sensitive to
Fig. 3. Channels formed with T8A-MiRP1 are more sensitive to SMX. Currents and fits as in Fig. 2. (A) Current–dose relationship for channels formed with
wild-type MiRP1 (open circles) and T8A-MiRP1 (filled circles) in the presence of increasing amounts of TMPySMX. Data from peak currents at 240 mV after a
prepulse to 120 mV by using the standard protocol. Fits give values for wild-type MiRP1 of Ki 5 380 6 40 mgyml and n 5 1.8 6 0.3 and for T8A-MiRP1 of Ki 5
210 6 30 mgyml and n 5 1.9 6 0.2; 13 cells in each case. (B) Current–dose relationships in the presence of TMP for wild-type MiRP1 (open circles) and T8A-MiRP1
(filled circles). Fits give values for Ki and n of 71 6 12 mgyml and 1.8 6 0.4 for wild-type MiRP1 and 75 6 9 mgyml and 1.9 6 0.3 for T8A-MiRP1; 5 cells each case.
The data thus suggest inhibition was cooperative and two TMP molecules were required to block. (C) Whole-cell currents recorded from channels formed with
wild-type MiRP1 (WT) and T8A-MiRP1 (T8A) in the absence (left column) or presence of 633 mgyml of SMX (1SMX). Scale bars represent 50 pA and 40 pA for
wild type and T8A, respectively, and 1 s. (D) Current–dose relationships in the presence of SMX for wild-type MiRP1 (open circles) and T8A-MiRP1 (filled circles).
Fits give values for Ki and n of 2,600 6 200 mgyml and 1.6 6 0.6 for wild-type MiRP1 and 675 6 60 mgyml and 1.4 6 0.2 for T8A-MiRP1; 6 cells each case.
Table 1. Gating parameters for wild-type (WT)- and T8A-MiRP1-containing channels
Channel
(no. of cells)
Activation
V1y2, mV
Activation
slope, mV
Deactivation
tfast, s
Deactivation
tslow, s
Deactivation ratio
Ifasty(Ifast1Islow)
WT (10)
Control 220 6 5 9.5 6 1.4 0.4 6 0.1 1.5 6 0.4 0.5 6 0.1
SMX 220 6 6 9.8 6 2.2 0.3 6 0.1 1.4 6 0.3 0.5 6 0.2
T8A (10)
Control 225 6 6 9.0 6 1.2 0.6 6 0.2 1.4 6 0.4 0.5 6 0.1
SMX 221 6 5 9.4 6 2.1 0.15 6 0.04 0.9 6 0.3 0.5 6 0.1
Activation and deactivation kinetics were estimated in whole-cell recordings in the absence and presence of 633 mg/ml SMX. By using the protocol in Fig. 2,
peak-tail currents at 240 mV were normalized and fit to the Boltzmann function: 1y{11exp[(V1y22V)yVS]}, where V1y2 is half-maximal voltage and VS the slope
factor in mV. Deactivation kinetics were fit to a double exponential function (I0 1 Ife(2tytf) 1 Ise(2tytS)) at 240 mV after a prepulse to 20 mV as in Fig. 3.
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drug inhibition showing ’50% block at this drug dose. Therefore,
with drug, A116V-MiRP1 channels passed ’1y4 of the current
carried by unblocked wild-type channels. These findings support
the notion that A116V-MiRP1 decreased the ability of the myo-
cardium to repolarize at baseline, placing our patient at increased
risk for drug-induced arrhythmia when exposed subsequently to
quinidine at therapeutic levels. We suggest superimposed heart
failure further reduced repolarization reserve to increase the like-
lihood of TdP (23).
Figs. 4C shows raw traces of currents passed by wild-type
MiRP1 and T8A-MiRP1 channels in the absence and presence
of 300 mgyml SMX. In the absence of drug, channels formed
with the T8A-MiRP1 were largely indistinguishable from wild
type, as expected (Table 1) (9). Although SMX at this dose did
not significantly affect wild-type channels, current through T8A-
MiRP1 channels was reduced to half the wild-type level (Fig. 4D;
n 5 5). Concordant with the observation that SMX speeds
deactivation of T8A-MiRP1 channels, peak current was reached
more rapidly in the presence of the drug (Fig. 4C), presumably
because of increased channel availability, as with a disease-
associated mutation of HERG that speeds deactivation (22).
These findings may explain why most patients receive
TMPySMX without incident (24) and others develop QT pro-
longation and TdP (25, 26). Although the large majority of
individuals carry KCNE2 genes encoding wild-type MiRP1,
T8A-MiRP1 appears to predispose to arrhythmia by increasing
the inhibitory effects of SMX, in part by speeding deactivation,
placing 1–2% of the population at increased risk for SMX-
induced arrhythmia.
Diseases caused by defects in single genes are rare (27). More
common disorders such as diabetes (28), breast cancer (29), or
hypertension (30) are thought to be caused by the combined
influence of multiple susceptibility genes. So, too, the response
of individual patients to drug therapy is expected to be influ-
enced by genomic variation, for example, because of differences
in drug metabolism or the structure or function of drug receptor
molecules. The most common type of DNA sequence variation,
SNPs, are observed at a frequency of ’1y500–1,000 nucleotides
in humans (31), and large-scale screening for SNPs (32) is now
under way to advance efforts to identify disease susceptibility
genes or to predict the response of individuals to drug therapies
(33). Previous studies have indicated that a prolonged QT
interval on a baseline electrocardiogram identifies individuals at
increased risk for drug-induced arrhythmia, especially when
administered medications that block cardiac potassium channels
(9, 11). This study argues for the value of a ‘‘pharmacogenetic’’
approach to drug treatment, because it demonstrates that com-
mon sequence variations can be clinically silent before drug
exposure yet increase the risk for life-threatening drug reactions.
With further identification of allelic variants that increase sus-
ceptibility to cardiac arrhythmia, preprescription genotyping
becomes a consideration.
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Fig. 4. Missense mutations and drug inhibition combine to diminish potassium flux. Simulated cardiac action potentials were used to study channels formed
with wild-type MiRP1, A116V-MiRP1 and T8A-MiRP1 with HERG in CHO cells. (A) Whole-cell currents for simulated action potentials with wild-type MiRP1 and
A116V-MiRP1 (*) in the absence and presence of 0.5 mgyml quinidine (1quinid). Scale bars represent 1.3 pAypF and 0.8 s. (Inset) Protocol: holding 280 mV,
voltage ramp from 40 to 280 mV, dVydt 5 271 mVys. (B) Normalized potassium flux assessed by measurement of area under the curve for simulated action
potentials in cells expressing wild-type MiRP1 (WT) or A116V-MiRP1 (A116V) in the presence of 0.5 mgyml quinidine (1quinid) normalized to wild-type channels
without drug. Currents were divided by cell capacitance before normalization. Each bar represents the mean 6 SEM for 6–10 cells. (C) Whole-cell currents for
simulated action potentials with wild-type MiRP1 and T8A-MiRP1 (*) in the absence and presence of 300 mgyml SMX. Scale bars represent 1.6 pAypF and 0.8 s.
(D) Normalized potassium flux assessed by measurement of area under the curve for simulated action potentials in cells expressing wild-type MiRP1(WT) and
T8A-MiRP1 (T8A) in the presence of 300 mgyml SMX normalized to wild-type channels without drug. Currents were divided by cell capacitance before
normalization. Each bar represents the mean 6 SEM for 7–10 cells.
Sesti et al. PNAS u September 12, 2000 u vol. 97 u no. 19 u 10617
PH
YS
IO
LO
G
Y
1. Roden, D. M., Lazzara, R., Rosen, M., Schwartz, P. J., Towbin, J. & Vincent,
G. M. (1996) Circulation 94, 1996–2012.
2. Ackerman, M. J. & Clapham, D. E. (1997) N. Engl. J. Med. 336, 1575–1586.
3. Keating, M. T. & Sanguinetti, M. C. (1996) Science 272, 681–685.
4. Schwartz, P. J., Priori, S. G. & Napolitano, C. (2000) in Cardiac Electrophys-
iology: From Cell to Bedside, eds. Zipes, D. P. Jalife, J. (Saunders, Philadelphia),
pp. 597–615.
5. Bennett, P. B., Yazawa, K., Makita, N. & George, A. L., Jr. (1995) Nature
(London) 376, 683–685.
6. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D. &
Keating, M. T. (1995) Cell 80, 795–803.
7. Wang, Q., Curran, M. E., Splawski, I., Burn, T. C., Millholland, J. M., VanRaay,
T. J., Shen, J., Timothy, K. W., Vincent, G. M., de Jager, T., et al. (1996) Nat.
Genet. 12, 17–23.
8. Splawski, I., Tristani-Firouzi, M., Lehmann, , M. H., Sanguinetti, M. C. &
Keating, M. T. (1997) Nat. Genet. 17, 338–340.
9. Abbott, G. W., Sesti, F., Splawski, I., Buck, M., Lehmann, M. H., Timothy,
K. W., Keating, M. T. & Goldstein, S. A. N. (1999) Cell 97, 175–187.
10. Roden, D. M. (1998) Pacing Clin. Electrophysiol. 21, 1029–1034.
11. Roden, D. M. (1998) Am. J. Cardiol. 82, 49I–57I.
12. Minardo, J. D., Heger, J. J., Miles, W. M., Zipes, D. P. & Prystowsky, E. N.
(1988) N. Engl. J. Med. 319, 257–262.
13. Donger, C., Denjoy, I., Berthet, M., Neyroud, N., Cruaud, C., Bennaceur, M.,
Chivoret, G., Schwartz, K., Coumel, P. & Gulcheney P. (1997) Circulation 96,
2778–2781.
14. Napolitano, C., Schwartz, P. J., Brown, A. M., Ronchetti, E., Bianchi, L.,
Pinnovala, A., Acquaro, G. & Priori, S. G. (2000) J. Cardiovasc. Electrophysiol.
11, 691–696.
15. Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K. & Sekiya, T. (1989) Proc.
Natl. Acad. Sci. USA 86, 2766–2770.
16. Abbott, G. W. & Goldstein, S. A. N. (1998) Quart. Rev. Biophys. 31, 357–398.
17. Davies, B. H. & Rocchiccioli, K. (1983) Pharmatherapeutica 3, 365–369.
18. Kates, R. E. (1983) Am. J. Cardiol. 52, 8C–13C.
19. Zema, M. J. & Mirando, T. (1983) Angiology 34, 32–39.
20. Blaser, J., Joos, B., Opravil, M. & Luthy, R. (1993) Infection 21, 206–209.
21. Joos, B., Blaser, J., Opravil, M., Chave, J. P. & Luthy, R. (1995) Antimicrob.
Agents Chemother. 39, 2661–2666.
22. Chen, J., Zou, A., Splawski, I., Keating, M. T. & Sanguinetti, M. C. (1999)
J. Biol. Chem. 274, 10113–10118.
23. Tomaselli, G. F., Beuckelmann, D. J., Calkins, R. D., Berger, Kessler, P. D., Lawrence,
J. H., Kass, D., Feldman, A. M. & Marban, E. (1994) Circulation 90, 2534–2539.
24. Girgis, I., Gualberti, J., Langan, L., Malek, S., Mustaciuolo, V., Costantino, T.
& McGinn, T. G. (1997) Chest 112, 646–653.
25. Lopez, J. A., Harold, J. G., Rosenthal, M. C., Oseran, D. S., Schapira, J. N. &
Peter, T. (1987) Am. J. Cardiol. 59, 376–377.
26. Weiner, I., D. Rubin, A., Marinez, E., Postman, J. & Herman, M. V. (1981) Mt.
Sinai J. Med. 48, 53–55.
27. Collins, F. S. (1995) Nat. Genet. 9, 347–350.
28. Mein, C. A., Esposito, L., Dunn, M. G., Johnson, G. C., Timms, A. E., Goy,
J. V., Smith, A. N., Sebag-Montefiore, L., Merriman, M. E., Wilson, A. J., et
al. (1998) Nat. Genet. 19, 297–300.
29. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K.,
Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994)
Science 266, 66–71.
30. Pratt, R. E. & Dzau, V. J. (1999) Hypertension 33, 238–247.
31. Cooper, D. N., Smith, B. A., Cooke, H. J., Niemann, S. & Schmidtke, J. (1985)
Hum. Genet. 69, 201–205.
32. Wang, D. G., Fan, J. B., Siao, C. J., Berno, A., Young, P., Sapolsky, R.,
Ghandour, G., Perkins, N., Winchester, E., Spencer, J., et al. (1998) Science 280,
1077–1082.
33. Collins, F. S., Guyer, M. S. & Charkravarti, A. (1997) Science 278, 1580–
1581.
10618 u www.pnas.org Sesti et al.
